Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren Long-term Safety Extension in Hypertension
NCT00171405Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of aliskiren in hypertension (HTN), sponsored by Novartis. Primary endpoint: Assessment of safety through reporting of adverse events and serious adverse events at 12 months. Started Jun 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00171405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171405.